New Drug Approvals

DECEMBER 24, 2023

Capivasertib C 21 H 25 ClN 6 O 2 428.915 1143532-39-1 AZD 5363 4-amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE FDA APPROVED 11/16/2023, To treat breast cancer that meets certain disease criteria, Truqap Capivasertib , sold under the brand name Truqap , is an anti-cancer medication used for the treatment of breast canc

FDA Approval 63

FDA Approval FDA Production Therapies 63

Drug Patent Watch

DECEMBER 24, 2023

Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in seven NDAs. It is available from one supplier.… The post New patent expiration for Otsuka drug ABILIFY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

New Drug Approvals

DECEMBER 24, 2023

Eplontersen AKCEA-TTR-LRx ION-682884 FREE ACID ISIS-682884 FREE ACID UNII 0GRZ0F5XJ6 CAS number1637600-16-8 ALL-P-AMBO-5-O-(((6-(5-((TRIS(3-(6-(2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYLOXY)HEXYLAMINO)-3-OXOPROPOXYMETHYL))METHYL)AMINO-5-OXOPENTANAMIDO)HEXOXY))PHOSPHO)-2-O-(2-METHOXYETHYL)-5-METHYL-P-THIOURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLCYTIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLURIDYLYL-(3-O->5-O)-2-O-(2-METHOXYETHYL)-5-METHYLURIDYLYL-(3-O->5-O)-2-O-(2-M

Clinical Trials 63

Clinical Trials FDA Clinical Pharmacology Pharmacokinetics 63

Drug Patent Watch

DECEMBER 24, 2023

Annual Drug Patent Expirations for ABILIFY+MYCITE+KIT Abilify Mycite Kit is a drug marketed by Otsuka and is included in one NDA. It is available from one supplier. There are twenty-nine… The post New patent expiration for Otsuka drug ABILIFY MYCITE KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

DECEMBER 24, 2023

This chart shows the pharmaceutical companies with the most lotion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most lotion dosed drugs… The post Which pharmaceutical companies have the most lotion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drugs 59